Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Total Non-current Liabilities
All obligations due after more than one year.
Nuvalent, Inc.NASDAQ: NUVL
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 284.1% from a year ago
Total non-current liabilities stood at $75.73M at the end of Q1 FY2026, up 284.1% from a year earlier and up 3.5% from the prior quarter.
Context
- Total non-current liabilities amounted to 5.7% of total assets at the end of Q1 FY2026, up 3.9 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +284.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 73.2M USD
- Year-over-year change
- +308.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.2M | +308.0% |
| FY2024 | 2024-12-31 | 17.94M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +284.1% is the highest of 9, against a peer median of +16.9%.
- Total non-current liabilities amounts to 5.7% of total assets for NUVL, versus a peer median of 29.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.27B USD | +2.9% | -9.2% | 43.9% | |
| Jun 2026 | $1.92B USD | +31.0% | +21.9% | 99.6% | |
| Sep 2026 | $1.38B USD | +100.5% | +54.5% | 79.2% | |
| Sep 2026 | $767.38M USD | +264.8% | -7.6% | 30.0% | |
| Jun 2026 | $217.7M USD | -3.1% | +21.1% | 28.6% | |
| Jun 2026 | $108.94M USD | +37.0% | +134.2% | 3.5% | |
| Sep 2026 | $90.7M USD | -15.2% | +10.0% | 20.5% | |
| Mar 2026 | $75.73M USD | +284.1% | — | 5.7% | |
| Jun 2026 | €24.25M EUR | -56.4% | +57.6% | 5.2% | |
| Peer median (excluding NUVL) | — | +16.9% | +21.5% | 29.3% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 68.53M | 241.81M | 335.39M | 145.69M | 261.75M |
| Short-term Investments | 219.59M | 230.36M | 384.52M | 972.61M | 1.11B |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.83M | 6.58M | 14.15M | 0 |
| Total Current Assets | 290.63M | 477.99M | 726.49M | 1.13B | 1.39B |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.2M | 4.47M | 5.9M | 9.3M | 20.28M |
| Total Non-current Assets | 3.2M | 4.47M | 5.9M | 9.3M | 20.28M |
| Total Assets | 293.82M | 482.46M | 732.38M | 1.14B | 1.41B |
| Account Payables | 2.89M | 7.2M | 9.27M | 5.23M | 30.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.16M | 7.43M | 7.33M | 10.45M | 16.94M |
| Total Current Liabilities | 8.79M | 19.48M | 31.82M | 54.02M | 91.17M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 17.94M | 73.2M |
| Total Non-current Liabilities | 0 | 0 | 0 | 17.94M | 73.2M |
| Total Liabilities | 8.79M | 19.48M | 31.82M | 71.96M | 164.37M |
| Common Stock | 5K | 6K | 7K | 8K | 8K |
| Retained Earnings | (78.22M) | (160.08M) | (286.3M) | (547.05M) | (972.43M) |
| Accumulated OCI | (228K) | (494K) | 31K | (59K) | 2.35M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 285.04M | 462.98M | 700.56M | 1.07B | 1.25B |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (68.53M) | (241.81M) | (335.39M) | (145.69M) | (261.75M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.